BTBP(SH:600161) Mei Ri Jing Ji Xin Wen·2025-10-24 10:19Group 1 - The company TianTan Bio (SH 600161) held its 26th meeting of the 9th Board of Directors on October 23, 2025, in Beijing, where it reviewed the proposal to adjust the blood source management structure [1] - For the first half of 2025, the company's revenue composition was 99.68% from the biopharmaceutical sector and 0.32% from other businesses [1] - As of the report date, TianTan Bio's market capitalization was 37.7 billion yuan [1] Group 2 - The Chinese innovative drug sector has sold overseas authorizations worth 80 billion USD this year, indicating a hot secondary market for biopharmaceuticals [1] - Despite the thriving secondary market, the primary market for fundraising in the biopharmaceutical sector is experiencing a cooling trend [1]